Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

GDUFA II: ANDAs, Not Facilities Will Govern Revenue

Sep 26 2016

• By Derrick Gingery

FDA entrance sign 2016

Related Content

Generic User Fees Need Small Business Waiver, Firms Say; Congress May Agree

Jun 24 2013

Generic User Fees: Small Firms Might Get Waivers; CMOs Want Them Too

Sep 29 2014

Generic Facility Fee Unlikely To Be Charged Until A Few Months After GDUFA Implementation

Dec 19 2011

ANDA Reviews: First-Cycle Desired, But Two-Cycles OK?

Jul 27 2015

FDA's Generic Drug Workload, Productivity Beating Budget Estimates

Feb 22 2016

GDUFA II: Facility Fees Might Be Deferred Until ANDA Approval

Jun 16 2015

GDUFA Negotiations Shift To 'Tiered' Fee Models

Jul 28 2016

ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal

Sep 24 2016

ANDA User Fees Offer Sponsor Relief, But More Facility Pain

Jul 26 2016

Will PDUFA VI Fee Structure Changes Slow Revenue Growth?

Jul 25 2016

ANDA Approvals, Submissions Decline With New Review Goal Coming

Aug 12 2016

GDUFA II Will Include Small Business Relief, Priority ANDA Reviews

Aug 31 2016

Additional Topics

United States Review Pathway Drug Review Manufacturing Regulation BioPharmaceutical

More from Review Pathways

More from Pathways & Standards

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window